Breast cancer in the setting of HIV. by Palan, M et al.
SAGE-Hindawi Access to Research
Pathology Research International
Volume 2011, Article ID 925712, 4 pages
doi:10.4061/2011/925712
Case Report
Breast Cancer in the Setting of HIV
Mitul Palan,1 Sami Shousha,2 Jonathan krell,1 and Justin Stebbing1
1Department of Medical Oncology, The Hammersmith Hospitals NHS Trust,
and Charing Cross Hospital, Imperial College Healthcare NHS Trust, Fulham Palace Road, London W6 8RF, UK
2Department of Histopathology, and Charing Cross Hospital, Imperial College Healthcare NHS Trust,
Fulham Palace Road, London W6 8RF, UK
Correspondence should be addressed to Mitul Palan, mitul.palan06@imperial.ac.uk and
Justin Stebbing, j.stebbing@imperial.ac.uk
Received 29 November 2010; Revised 5 April 2011; Accepted 5 April 2011
Academic Editor: Liron Pantanowitz
Copyright © 2011 Mitul Palan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Oncogenesis in immunocompromised patients occurs due to a number of factors including reduced immune surveillance or other
viral pathogens. Breast cancer, unlike other non-AIDS-defining cancers, does not appear associated and has rarely been reported.
We describe a case with evidence of immune reactivity around the tumor, but not in the tumor itself.
1. Introduction
Very few cases of breast cancer in HIV-infected women are
recorded in the literature; approximately 46 HIV-infected
women to this date have been recorded. According to
the World Health Organization, approximately 33.4 million
people (adults and children) in the world were living with
HIV in 2008, the majority of which resided in sub-Saharan
Africa [1]. A very wide range of cancers have been associated
with an increased incidence in people living with HIV [2, 3].
As well as neoplasms such as Kaposi’s sarcoma [4] and Non-
Hodgkin’s lymphoma [5], a focus of recent research has been
the non-AIDS-defining cancers, that is, tumors other than
Kaposi sarcoma, non-Hodgkin lymphoma, and cancer of
the uterine cervix, in the setting of HIV. However, of the
non-AIDS-defined cancers, breast cancer does not seem to
increase in incidence within the HIV-infected population.
This relationship between the two diseases has been noted
worldwide, but few explanations have been forwarded as to
the exact causative/noncausative relationship that the two
may partake in.
This paper looks to evaluate the relationship between the
HIV and breast cancer, and we propose some theories as to
why HIV infection may actually protect against breast tumor
development.
2. Case Vignette
A 44-year-old HIV-positive lady presented with a right breast
mass in the upper outer quadrant and was diagnosed with
a triple negative (i.e., oestrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor 2
(HER2) negative), grade 3 invasive ductal carcinoma (IDC),
15mm × 15mm in size, with zero out of 3 sentinel nodes
involved.
She initially noticed a lump in her right breast, alongside
skin and shape changes in the breast and nipple discharge.
There was no history of oral contraceptive use, nor any family
history of breast/ovarian cancer. Her CD4 count measured
450 cells/mm3 with an HIV-1 viral load of approximately
500 copies/mL. Mammography, ultrasound, and core biopsy
of the right breast confirmed the presence of the tumor.
Figures of her breast pathology may be seen below (Figures
1 and 2). CD4 and CD8 lymphocyte staining of the tissue
sample showed significant lymphocytic infiltration adjacent
to the tumor (but not within it).
The patient’s treatment included a wide local excision
of the lump with right axillary sentinel lymph node biopsy.
The patient underwent 6 cycles of FEC75 chemotherapy
requiring substantial dose reductions and G-CSF support,
while remaining concurrently on HAART. A bone scan and
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Figure 1: Low (a) and high (b) power images of our patient’s invasive ductal carcinoma of the breast. Sections were stained with haematox-
ylin and eosin. (a) shows a large area of central tumor necrosis with a peripheral rim of viable tumor cells. (b) shows invasive tumor cells
with high nuclear grade.
(a) (b)
Figure 2: CD4 (a) and CD8 (b) staining of the tumor sections. Both cell populations were found adjacent to, but not infiltrating, the tumor.
a CT showed no sign of distant metastases. At the time of
submission, she is completing her chemotherapy.
3. Discussion
While a number of neoplasms are well associated with HIV
infection [4–7], non-AIDS-defining tumors [8] have more
complex aﬃliations to HIV—some seem to also increase in
incidence with infection, for example, lung cancer, myeloma,
anal cancers [7, 9], while it is still debated whether others
(e.g., breast cancer, head and neck cancer [10]) have an
increased incidence due to HIV.
Few studies have delved into explaining the link between
HIV and breast cancer. This is not particularly surprising
however, as only 48 cases of breast cancer have been noted
in HIV-positive people to date [11]. This number may be
contested due to lack of case presentation (e.g., poorer
socioeconomic groups/people of the third world less likely
to seek medical care) or that women with HIV may have
a reduced lifespan (and therefore are less likely to reach an
age at which breast cancer may occur) [12]. A study in 1,416
HIV-positive Thai women, with an average age of 40.8 years
over 5 years, found breast cancer to be the most prominent
(9.5%) non-AIDS-defining tumors (42 cases of non-AIDS
tumors overall) occurring [13]. It is important however to
note though that the number of patients with breast cancer
amounted to 4: approximately 0.28% of the percentage of
women, a figure not too dissimilar to what one would expect
in a female cohort such as this.
The majority of studies have found no diﬀerence in the
incidence of breast cancer in HIV-positive women and the
HIV-negative population [11]. An American study by Frisch
et al. found the relative risk of developing breast cancer
after HIV infection was 1.1, that is, HIV infection had little
impact on breast cancer incidence [7], and other studies have
supported this [9, 14]. In a sub-Saharan Tanzanian popula-
tion, there was a small, yet statistically significant decrease
in breast cancer incidence in the post-AIDS epidemic period
(1983–1996), compared to the pre-AIDS period (1968–1983)
[4]. Data from Rwanda additionally shows a low number
of breast cancer cases despite a high HIV prevalence [15].
Reviews concur with these findings. For example, in South
Africa, no trend has been observed [16].
People with HIV may develop cancer due to impaired
immune surveillance, dysregulation of growth factors or
cytokines, or imbalance between proliferation and diﬀeren-
tiation [17]. As can be observed in our case, and in a number
of other reported cases [18], the pathology of HIV-positive
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breast cancer patients is in stark contrast to noninfected
women in the population. A reduction in immune function
could be a reason why breast cancer prevalence remains low
in patients with HIV [7, 19]. Pantanowitz investigated the
pathology of HIV-positive breast cancer cases, finding that
the immune response to these neoplasms was considerably
less compared to that found in breast cancer in nonaﬀected
women [3]. Immunosuppression is a large factor in the
pathogenesis of many AIDS-related cancers [18, 20, 21].
HPV, associated with anal and cervical cancer (particularly
in the immunocompromised), may induce oncogenesis by
altering cell-cycle control—either deactivating tumor-sup-
pressor genes or up regulating certain oncogenes [22]. There
is continued debate whether HIV itself may cause dysregu-
lation of cell proliferation by insertion of provirus nuclear
material near/within human oncogenes [20].
The prognostic significance of stromal lymphocytic
infiltration in breast cancer is disputed [23–26]. Previously,
it has been linked to a poor prognosis [3, 27] (e.g., CD4- and
CD8-T lymphocyte infiltration has been associated with high
grade intraductal carcinomas [18]). This is not a relationship
one would expect between the two as the immune system in
nonimmunocompromised individuals plays a pivotal role in
removing cancerous cells [18]. However, the control over cell
proliferation here is slightly more complex. CD4- and CD8-
T lymphocytes are implicated in acquired immune responses
to cancer, but are tightly regulated by T regulatory cells [28].
Various studies have shown that T regulatory cells are found
in abundance in neoplastic breast tissues, both in situ and
in invasive carcinomas—their recruitment in intratumoral
and peritumoral tissue may enable malignant cells to evade
the host immune response, and as such may represent a
marker of breast cancer progression [28, 29]. This may
explain the absence of intratumoral lymphocytic infiltration,
as seen in our patient (Figures 1 and 2). In HIV, however, the
reduction in T cell count suggests that with a decreased num-
ber of T regulatory cells (along with some CD4- and CD8-
T lymphocytes), the host is unable to restrict an immune
response to cancer growth. This may indirectly benefit the
patient from developing breast cancer, but perhaps not
from other cancers [8]. Studies in posttransplant, non-HIV
immunocompromised women (a similar subgroup to HIV-
positive women) also support this proposition [16, 30].
HAART-induced restoration of immune function with
treatment [31] may prevent initial breast tumorigenesis. An-
tiretrovirals such as ritonavir have been implicated in target-
ing both viral and tumorigenic proteins [32] that may play
some part in breast cancer proliferation‘or tumor progres-
sion/resistance [33, 34]. These drugs may decrease the avail-
ability/activity of proangiogenic factors [5, 35], interfere with
other oncogenic cytokine signalling pathways [31], or target
intracellular mitogenic signalling pathways (which tumors
use to proliferate [36, 37]). There is also some evidence to
suggest that HIV viral proteins may induce tumor cell cyto-
toxicity and apoptosis [38]. Excessive fatty tissue contributes
to breast cancer in postmenopausal women (as peripheral
conversion of androgens to active oestradiol stimulates breast
epithelial proliferation). The nutrient redistribution in HIV
patients may have a role here [39–41], and the reduction
in peripheral fat stores could reduce peripheral oestradiol
conversion in these women. Overall, this seems an unlikely
occurrence, especially in the few cases on breast cancer in
HIV patients found.
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